> Millendo Therapeutics bought France’s Alizé Pharma. Statement
> Summit Therapeutics offloaded the Latin American rights to its Clostridium difficile infection drug. Statement
> The EMA’s drug review committee recommended the approval of TiGenix and Takeda’s allogeneic stem cell therapy. Release
> Active Biotech warned it must sell a property or otherwise raise money before the end of February, otherwise it “will not have funding for the coming twelve-month period.” Statement
> The FDA awarded qualified infectious disease product status to Basilea Pharmaceutica’s ceftobiprole. Release
> Ablynx posted data from a Japanese ethno-bridging study of caplacizumab. Statement
> BiomX bought RondinX to expand its microbiome discovery and development capabilities. Release